Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19

By sjmartinez • October 10, 2022

Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs R, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ. Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19. Clin Infect Dis. 2022 Oct 10:ciac818. doi: 10.1093/cid/ciac818. Epub ahead of print. PMID: 36210483.

Tags: covid-19, Infectious Diseases, Publications, RNA, SARS-CoV-2, Symptom duration

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

The Cost and Intermediate Cost-Effectiveness of a Randomized Control Trial Delivering U=U Messaging to Increase HIV Testing Among South African Men

Smith PJ, Davey DJ, Schmucker L, Bekker LG, Medina-Marino A, Thirumurthy H, Buttenheim AM, Meyer-Rath G. The Cost and Intermediate Cost-Effectiveness of a Randomized Control[...]

Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges

Murdande S, Mishra S, Munoz A, Fox K, D'Assumpcao C. Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges. Infect Prev Pract. 2026[...]